NEW YORK AND SAN DIEGO (Sept. 3, 2014)-- The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX - 2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships. (cancerresearch.org)
When the drugs were coupled with other immunotherapy agents, the anti-cancer effect can be even greater, they report. (sciencedaily.com)
As in other immunotherapy trials, Tanyi has found that some patients were able to stop the cancer's progression with continued booster shots of vaccine. (washingtonpost.com)